Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018

Drugs in R and D

Volumn 5, Issue 6, 2004, Pages 339-342

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GADOFOSVESET; GADOLINIUM CHELATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; THALLIUM;

ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; BURNING SENSATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; COOPERATION; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DRUG APPROVAL; DRUG EXCRETION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG TRANSPORT; EXERCISE TEST; FEASIBILITY STUDY; FEMALE SEXUAL DYSFUNCTION; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; JAPAN; LERICHE SYNDROME; LICENCE; META ANALYSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATENT; PATIENT MONITORING; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; PRURITUS; RADIOCARDIOGRAPHY; RESPONSIBILITY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEXUAL AROUSAL; SYSTEMATIC REVIEW; TECHNOLOGY; THREE DIMENSIONAL IMAGING; THROMBOSIS; UNITED STATES; URINARY EXCRETION;

CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; GADOLINIUM; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; ORGANOMETALLIC COMPOUNDS; VASCULAR DISEASES;

EID: 10344266961     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405060-00005     Document Type: Article

References (13)

1. EPIX Medical Inc. EPIX Submits MS-325 New Drug Application to FDA. Media Release: 16 Dee 2003. Available from URL: http://www.epixmed.com
2. EPIX Medical Inc. EPIX Announces FDA Acceptance of Filing of MS-325 NDA; Review of First Drug Developed for MR Vascular Imaging on Track. Media Release: 17 Feb 2004. Available from URL: http://www.epixmed.com
3. EPIX Medical Inc. EPIX Phase II Dose-Ranging Study Published in Journal Radiology. Media Release: 2 Dec 2003. Available from URL: http://www.epixmed.com
4. EPIX Medical Inc. EPIX Completes Enrollment of Phase III Clinical Program for MS-325; Milestone Moves MS-325 Closer to NDA Filing. Media Release: 3 Feb 2003. Available from URL: http://www.epixmed.com
5. EPIX Medical Inc. EPIX Initiates MS-325 Clinical Trial in High Resolution Vascular MRA; Study to Explore the Potential of MR Vessel Wall Imaging. Media Release: 8 Jul 2004. Available from URL: http://www.epixmed.com
6. EPIX Medical Inc. Schering Submits MS-325 for Magnetic Resonance Angiography Marketing Approval in the EU; Second Regulatory Filing Positions Innovative Blood Pool Agent For MRA. Media Release: 7 Jun 2004. Available from URL: http://www.epixmed.com
7. EPIX. EPIX Initiates MS-325 Clinical Trial for Cardiac Imaging; Blood Pool Contrast to Exploit Advanced MRI Technologies. Media Release: 12 Jul 2004. Available from URL: http://www.epixmed.com
8. EPIX Medical Inc. EPIX Granted Patent for MS-325 Composition of Matter. Media Release: 13 Jan 2004. Available from URL: http://www.epixmed.com
9. EPIX Medical and Mallinckrodt announce completion of MS-325 phase I dose escalation study increased dose level administered to patients. PR Newswire [online, 2 pages], 24 Mar 1998. Available from URL: http://www.newspage.com
10. EPIX Medical Inc. Positive phase III MS-325 results reported at ACC: EPIX Medical's cardiovascular trial succeeds in primary endpoint. Media Release [3 pages], 18 Mar 2002. Available from URL: http://www.epixmed.com
11. EPIX Medical Inc. EPIX Medical announces presentation of additional MS-325 phase II clinical trial results: webcast scheduled after presentation. Media Release [2 pages]. 25 Sep 2001. Available from URL: http://www.gilead.com
12. EPIX Medical Inc. EPIX Medical announces additional MS-325 phase II clinical trial results: FDA supports expansion of target indication. Media Release [4 pages], 27 Sep 2001. Available from URL: http://www.epixmed.com
13. EPIX Medical Inc. EPIX Reports New Positive Phase III MS-325 Results at European Congress of Radiology; Second Pivotal Cardiovascular Trial Meets Primary Endpoints, Confirms Earlier Data. Media Release: 7 Mar 2003. Available from URL: http://www.epixmed.com